Neuropace
NPCE
54 hedge funds and large institutions have $176M invested in Neuropace in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 5 closing their positions.
285% more call options, than puts
Call options by funds: $381K | Put options by funds: $99K
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
32% more funds holding
Funds holding: 41 → 54 (+13)
13% more capital invested
Capital invested by funds: $156M → $176M (+$20.2M)
10.51% less ownership
Funds ownership: 57.65% → 47.15% (-11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.18M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.3M |
| 3 |
Goldman Sachs
New York
|
+$1.99M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.08M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$673K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$34.8M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$5.64M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.36M |
| 4 |
KLC
Kent Lake Capital
Reno,
Nevada
|
-$390K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$260K |
NPCE Hedge Fund Activity: Q1 2024 in Review
54 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q1 2024, worth a combined $176M — up 13% from $156M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new NPCE positions and 5 closed out — a net gain of 13 holders — while 19 added to existing stakes and 13 trimmed.
The largest buyer was Millennium Management, adding an estimated $6.18M. The largest seller was Morgan Stanley, cutting an estimated $34.8M.
- 54 institutional investors held Neuropace (NPCE) as of Q1 2024, up from 41 in Q4 2023.
- Funds reported $176M of Neuropace stock for Q1 2024, up 13% quarter-over-quarter.
- 18 funds opened new Neuropace positions in Q1 2024 and 5 closed out, a net change of +13 holders.
- The largest Neuropace buyer in Q1 2024 was Millennium Management, an estimated $6.18M added.
- The largest Neuropace seller in Q1 2024 was Morgan Stanley, an estimated $34.8M sold.
Based on aggregated 13F filings for Q1 2024.